Bristol Myers Squibb Co · NYSE · Pharmaceutical Preparations · also CELG-RI
The company raised 2026 revenue guidance to $49.75 billion to $50.25 billion but lowered non-GAAP EPS guidance to $6.35 to $6.55, including a $(0.60) impact from Acquired IPRD and licensing income.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 9, 2026 | Cristian Massacesi EVP,Chief Med Offr,Head of Dev | Sold | 6,249 | $64.57 | $403,498 |
| Aug. 25, 2026 | Phil M. Holzer SVP and Controller | Sold | 500 | $67.50 | $33,750 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedBristol Myers Squibb beats Q3 2026 non-GAAP EPS at $1.35 vs $1.22 consensus and raises revenue guidance, but cuts full-year EPS outlook to $6.35 to $6.55 on $0.60 acquired IPRD charges